

Francesco A Piazza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3751259/publications.pdf>

Version: 2024-02-01

138
papers

3,177
citations

159585

30
h-index

182427

51
g-index

142
all docs

142
docs citations

142
times ranked

4452
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Dyskeratosis Congenita and Cancer in Mice Deficient in Ribosomal RNA Modification. <i>Science</i> , 2003, 299, 259-262. | 12.6 | 387 |
| 2 | The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. <i>Journal of Clinical Investigation</i> , 1999, 104, 115-121. | 8.2 | 134 |
| 3 | ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328. | 1.6 | 132 |
| 4 | Multiple myeloma cell survival relies on high activity of protein kinase CK2. <i>Blood</i> , 2006, 108, 1698-1707. | 1.4 | 123 |
| 5 | The theory of APL. <i>Oncogene</i> , 2001, 20, 7216-7222. | 5.9 | 103 |
| 6 | Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. <i>Leukemia</i> , 2012, 26, 1174-1179. | 7.2 | 94 |
| 7 | Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. <i>Blood</i> , 2013, 121, 3843-3854. | 1.4 | 85 |
| 8 | ROBUST: First report of phase III randomized study of lenalidomide/R ² CHOP (R ² CHOP) vs placebo/R ² CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 36-37. | 1.7 | 82 |
| 9 | Protein Kinase CK2 Inhibition Down Modulates the NF- κ B and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. <i>PLoS ONE</i> , 2013, 8, e75280. | 2.5 | 75 |
| 10 | Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress-Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response. <i>Clinical Cancer Research</i> , 2012, 18, 1888-1900. | 7.0 | 71 |
| 11 | <i>STAT3</i> mutation impacts biological and clinical features of T-LGL leukemia. <i>Oncotarget</i> , 2017, 8, 61876-61889. | 1.8 | 67 |
| 12 | Protein kinase CK2 regulates AKT, NF- κ B and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 292-300. | 7.2 | 55 |
| 13 | Disruption of PLZP in Mice Leads to Increased T-Lymphocyte Proliferation, Cytokine Production, and Altered Hematopoietic Stem Cell Homeostasis. <i>Molecular and Cellular Biology</i> , 2004, 24, 10456-10469. | 2.3 | 53 |
| 14 | Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. <i>Oncologist</i> , 2019, 24, e720-e729. | 3.7 | 52 |
| 15 | Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. <i>British Journal of Haematology</i> , 2019, 185, 940-944. | 2.5 | 49 |
| 16 | Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747. | 1.4 | 49 |
| 17 | Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. <i>Haematologica</i> , 2015, 100, e515-e518. | 3.5 | 48 |
| 18 | Hyperforin Blocks Neutrophil Activation of Matrix Metalloproteinase-9, Motility and Recruitment, and Restrains Inflammation-Triggered Angiogenesis and Lung Fibrosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 492-500. | 2.5 | 47 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. <i>Journal of Hematology and Oncology</i> , 2013, 6, 78. | 17.0 | 46 |
| 20 | Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. <i>British Journal of Haematology</i> , 2007, 138, 594-602. | 2.5 | 44 |
| 21 | Peripheral nervous system involvement in lymphomas. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 5-18. | 3.1 | 44 |
| 22 | Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. <i>Leukemia</i> , 2007, 21, 1060-1069. | 7.2 | 40 |
| 23 | Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. <i>BMC Cancer</i> , 2010, 10, 526. | 2.6 | 39 |
| 24 | Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. <i>Oncotarget</i> , 2015, 6, 42130-42149. | 1.8 | 39 |
| 25 | In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. <i>Cancers</i> , 2019, 11, 1939. | 3.7 | 39 |
| 26 | 3-(2,4-Dichlorophenyl)-4-(1-methyl-1 <i>H</i> -indol-3-yl)-1 <i>H</i> -pyrrole-2,5-dione (SB216763), a Glycogen Synthase Kinase-3 Inhibitor, Displays Therapeutic Properties in a Mouse Model of Pulmonary Inflammation and Fibrosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 785-794. | 2.5 | 36 |
| 27 | Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 277, L240-L250. | 2.9 | 35 |
| 28 | Role of protein kinases CK1 \pm and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways. <i>Journal of Hematology and Oncology</i> , 2017, 10, 157. | 17.0 | 32 |
| 29 | HSP70/HSF1 axis, regulated <i>via</i> a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2019, 145, 3089-3100. | 5.1 | 32 |
| 30 | Towards a new age in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2007, 86, 159-172. | 1.8 | 31 |
| 31 | The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. <i>Haematologica</i> , 2022, 107, 868-876. | 3.5 | 31 |
| 32 | Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. <i>Oncotarget</i> , 2015, 6, 6544-6552. | 1.8 | 31 |
| 33 | Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Leukemia</i> , 2020, 34, 1462-1466. | 7.2 | 30 |
| 34 | Inactivation of CK1 \pm in multiple myeloma empowers drug cytotoxicity by affecting AKT and β -catenin survival signaling pathways. <i>Oncotarget</i> , 2017, 8, 14604-14619. | 1.8 | 30 |
| 35 | Aberrant expression of <i>CD</i> 10 and <i>BCL</i> 6 in mantle cell lymphoma. <i>Histopathology</i> , 2017, 71, 769-777. | 2.9 | 29 |
| 36 | Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. <i>European Journal of Cancer</i> , 2017, 72, 103-111. | 2.8 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Novel players in multiple myeloma pathogenesis: Role of protein kinases CK2 and GSK3. <i>Leukemia Research</i> , 2013, 37, 221-227. | 0.8 | 28 |
| 38 | NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. <i>Cells</i> , 2020, 9, 768. | 4.1 | 27 |
| 39 | Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. <i>Oncotarget</i> , 2017, 8, 53053-53067. | 1.8 | 27 |
| 40 | Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 612-620.e5. | 0.4 | 26 |
| 41 | CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cellsâ€™T-Cell Interaction. <i>Blood</i> , 1999, 93, 1277-1286. | 1.4 | 25 |
| 42 | Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2017, 178, 81-93. | 2.5 | 25 |
| 43 | Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 678-685.e4. | 0.4 | 25 |
| 44 | Targeting CK2-driven non-oncogene addiction in B-cell tumors. <i>Oncogene</i> , 2016, 35, 6045-6052. | 5.9 | 24 |
| 45 | BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. <i>British Journal of Haematology</i> , 2019, 185, 193-197. | 2.5 | 24 |
| 46 | B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation. <i>Cancer</i> , 2000, 89, 1259-1268. | 4.1 | 23 |
| 47 | Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. <i>Oncotarget</i> , 2017, 8, 110727-110731. | 1.8 | 23 |
| 48 | Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma. <i>Cell Death Discovery</i> , 2019, 5, 98. | 4.7 | 22 |
| 49 | Inhibition of Leukocyte Elastase, Polymorphonuclear Chemoinvasion, and Inflammation-Triggered Pulmonary Fibrosis by a 4-Alkyliden-1 ² -lactam with a Galloyl Moiety. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 539-546. | 2.5 | 21 |
| 50 | Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. <i>Haematologica</i> , 2014, 99, 1826-1833. | 3.5 | 21 |
| 51 | Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome. <i>European Journal of Haematology</i> , 2020, 105, 468-475. | 2.2 | 21 |
| 52 | Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. <i>Blood Cancer Journal</i> , 2018, 8, 51. | 6.2 | 20 |
| 53 | Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2017, 35, 925-928. | 1.7 | 19 |
| 54 | The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 20. | 6.2 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | <p>Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia</p>. OncoTargets and Therapy, 2020, Volume 13, 9679-9688. | 2.0 | 19 |
| 56 | Targeting Protein Kinases in Blood Cancer: Focusing on CK1± and CK2. International Journal of Molecular Sciences, 2021, 22, 3716. | 4.1 | 18 |
| 57 | Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. Haematologica, 2017, 102, e140-e143. | 3.5 | 17 |
| 58 | Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. International Journal of Molecular Sciences, 2018, 19, 1512. | 4.1 | 16 |
| 59 | Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature. Hematological Oncology, 2020, 38, 823-826. | 1.7 | 16 |
| 60 | The Risk of Malignancies in Celiac Disease"A Literature Review. Cancers, 2021, 13, 5288. | 3.7 | 15 |
| 61 | Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. Leukemia, 2014, 28, 2094-2097. | 7.2 | 14 |
| 62 | Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis. Blood Cancer Journal, 2020, 10, 18. | 6.2 | 14 |
| 63 | Continuous treatment with Ibrutinib in 100 untreated patients with <i>TP</i>53 disrupted chronic lymphocytic leukemia: A real"life campus CLL study. American Journal of Hematology, 2022, 97, . | 4.1 | 14 |
| 64 | A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematological Oncology, 2019, 37, 508-512. | 1.7 | 13 |
| 65 | Infections in Patients with Myelodysplastic Syndrome/Acute Myeloid Leukemia Treated with Azacitidine: Report from a Single Center. Blood, 2014, 124, 5622-5622. | 1.4 | 13 |
| 66 | Modeling Acute Promyelocytic Leukemia in the Mouse: New Insights in the Pathogenesis of Human Leukemias. Blood Cells, Molecules, and Diseases, 2001, 27, 231-248. | 1.4 | 12 |
| 67 | CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cells"T-Cell Interaction. Blood, 1999, 93, 1277-1286. | 1.4 | 11 |
| 68 | Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution. European Journal of Haematology, 2021, 106, 737-739. | 2.2 | 10 |
| 69 | Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. PLoS ONE, 2021, 16, e0247717. | 2.5 | 10 |
| 70 | CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. Current Cancer Drug Targets, 2018, 18, 608-616. | 1.6 | 10 |
| 71 | Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma. Cancers, 2021, 13, 6089. | 3.7 | 10 |
| 72 | Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations. American Journal of Hematology, 2011, 86, E64-E66. | 4.1 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | New responsibilities for aged kinases in B-lymphomas. <i>Hematological Oncology</i> , 2020, 38, 3-11. | 1.7 | 8 |
| 74 | Tryptophan Deprivation Promotes an Adaptive Response and Contributes to Bioenergetics in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4511-4511. | 1.4 | 8 |
| 75 | Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BAiT Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4070. | 1.6 | 8 |
| 76 | Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. <i>American Journal of Hematology</i> , 2020, 95, 1473-1478. | 4.1 | 7 |
| 77 | Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. <i>Blood</i> , 2000, 96, 647-654. | 1.4 | 7 |
| 78 | Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 387-400. | 2.4 | 6 |
| 79 | High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2011, 18, 127-129. | 3.0 | 6 |
| 80 | Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2018, 36, 366-369. | 1.7 | 6 |
| 81 | Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. <i>Human Pathology</i> , 2019, 85, 251-259. | 2.0 | 6 |
| 82 | A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018, 132, 3118-3118. | 1.4 | 6 |
| 83 | Epidemiology and Risk Factors of Invasive Fungal Infections Among 795 Patients with Chronic Lymphocytic Leukemia from the Padua University. <i>Blood</i> , 2016, 128, 2527-2527. | 1.4 | 6 |
| 84 | Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 5453. | 3.7 | 6 |
| 85 | Global monitoring of influenza: potential contribution of national networks from a French perspective. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 387-393. | 4.4 | 5 |
| 86 | Analysis of Wnt and Hedgehog Pathways Regulating Protein Kinases CK1 and CK2 in Acute Myeloid Leukemia Cells and Stem Cells: Correlation with the Expression of Wnt and Hedgehog Targets and Biological and Clinical Features.. <i>Blood</i> , 2012, 120, 2501-2501. | 1.4 | 5 |
| 87 | Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis. <i>Current Signal Transduction Therapy</i> , 2011, 6, 88-98. | 0.5 | 4 |
| 88 | Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed/refractory aggressive B-cell lymphoma. <i>American Journal of Hematology</i> , 2018, 93, E386-E389. | 4.1 | 4 |
| 89 | Possible neuroleukemiosis in two patients with acute myeloid leukemia in complete bone marrow remission. <i>Journal of the Neurological Sciences</i> , 2018, 392, 63-64. | 0.6 | 4 |
| 90 | Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. <i>Hematological Oncology</i> , 2018, 36, 801-803. | 1.7 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL). <i>HemaSphere</i> , 2019, 3, e305. | 2.7 | 4 |
| 92 | Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry. <i>Acta Haematologica</i> , 2021, 144, 259-263. | 1.4 | 4 |
| 93 | Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , 2020, 4, e395. | 2.7 | 4 |
| 94 | Comparative Analysis of NK Receptor and T-Cell Receptor Repertoires in Patients with Chronic Myeloid Leukemia Treated with Different Tyrosine Kinase Inhibitors. <i>Blood</i> , 2014, 124, 5508-5508. | 1.4 | 4 |
| 95 | Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses.. <i>Blood</i> , 2016, 128, 2093-2093. | 1.4 | 4 |
| 96 | Protein Kinase CK1 β Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 733848. | 2.8 | 4 |
| 97 | Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study. <i>British Journal of Haematology</i> , 2019, 186, e13-e17. | 2.5 | 3 |
| 98 | Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From "Omics" Research. <i>Frontiers in Oncology</i> , 2020, 10, 802. | 2.8 | 3 |
| 99 | Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience. <i>Blood</i> , 2015, 126, 2710-2710. | 1.4 | 3 |
| 100 | Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 2427-2427. | 1.4 | 3 |
| 101 | Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 592-598. | 0.4 | 2 |
| 102 | A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib. <i>Annals of Hematology</i> , 2020, 99, 2715-2717. | 1.8 | 2 |
| 103 | Lymph node core needle biopsy in lymphoproliferative disorders" Authors'™ reply to Al'Abbadi and colleagues. <i>European Journal of Haematology</i> , 2021, 107, 297-298. | 2.2 | 2 |
| 104 | Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 682658. | 2.8 | 2 |
| 105 | Limbic Encephalitis with HU-Antibodies in T-cell Anaplastic Lymphoma. A Case Report. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6548. | 2.5 | 2 |
| 106 | Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922. | 1.4 | 2 |
| 107 | Multiple Myeloma Cells Survival and Proliferation Rely on High Levels and Activity of the Serine-Threonine Kinase CK2.. <i>Blood</i> , 2004, 104, 643-643. | 1.4 | 2 |
| 108 | High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. <i>Cancers</i> , 2022, 14, 338. | 3.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells. <i>Blood</i> , 2015, 126, 3876-3876. | 1.4 | 1 |
| 110 | Evaluation of Integrated CLL Scoring System (ICSS) in 420 Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 5563-5563. | 1.4 | 1 |
| 111 | Role of Protein Kinase CK2 in the Retinoic Acid-Induced Differentiation of Acute Promyelocytic Leukemia Cells.. <i>Blood</i> , 2007, 110, 879-879. | 1.4 | 1 |
| 112 | Hematopoietic-Specific CSNK2B Loss in Mice Causes Impaired Erythropoiesis. <i>Blood</i> , 2017, 130, 82-82. | 1.4 | 1 |
| 113 | PS1431 IDENTIFICATION OF THE TRUE HYPERDIPLOID MULTIPLE MYELOMA SUBSET BY COMBINING CONVENTIONAL KARYOTYPING AND FISH ANALYSIS. <i>HemaSphere</i> , 2019, 3, 659. | 2.7 | 1 |
| 114 | Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. <i>Blood</i> , 2020, 136, 33-34. | 1.4 | 1 |
| 115 | Anaemia during venetoclax ramp-up phase: Do not forget unusual causes. <i>International Journal of Laboratory Hematology</i> , 2022, 44, . | 1.3 | 1 |
| 116 | Metabolic control of epigenetic rearrangements in B cell pathophysiology. <i>Open Biology</i> , 2022, 12, 220038. | 3.6 | 1 |
| 117 | INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION. <i>Hematological Oncology</i> , 2017, 35, 145-146. | 1.7 | 0 |
| 118 | DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2017, 35, 194-196. | 1.7 | 0 |
| 119 | Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B- and T-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 345-346. | 1.7 | 0 |
| 120 | Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine. <i>Annals of Hematology</i> , 2018, 97, 2001-2003. | 1.8 | 0 |
| 121 | PRIMARY PANCREATIC LYMPHOMA: CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND OUTCOME IN A MULTICENTRIC ITALIAN EXPERIENCE. <i>Hematological Oncology</i> , 2019, 37, 455-456. | 1.7 | 0 |
| 122 | Immune Profiling of Plasma Cell Dyscrasias Reveals a Therapy Related T-Cell Modulation in Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e87. | 0.4 | 0 |
| 123 | Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2.. <i>Blood</i> , 2009, 114, 3840-3840. | 1.4 | 0 |
| 124 | Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma. , 2012, , 87-108. | | 0 |
| 125 | CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment. <i>Blood</i> , 2012, 120, 444-444. | 1.4 | 0 |
| 126 | Bortezomib-Dexamethasone As Induction Therapy for Light Chain Deposition Disease (LCDD): A Single Center Experience. <i>Blood</i> , 2012, 120, 5027-5027. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | R-Vemp Is a Safe and Effective Chemo-Immunotherapeutic Regimen In Elderly Unfit DLBCL Patients: Report From a Single Center-Experience. <i>Blood</i> , 2013, 122, 3042-3042. | 1.4 | 0 |
| 128 | Analysis of Major Infection Risk in 706 Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3321-3321. | 1.4 | 0 |
| 129 | Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively. <i>Blood</i> , 2016, 128, 4464-4464. | 1.4 | 0 |
| 130 | The Atypical Gtpase Rho Lies Downstream IL6/STAT3 and Regulates Myeloma Plasma Cells Adhesion/Motility. <i>Blood</i> , 2016, 128, 5661-5661. | 1.4 | 0 |
| 131 | HSP70-HSF1 Interplays Has a Role in the Pathogenesis of Chronic Lymphocytic Leukemia and Is a Druggable Target. <i>Blood</i> , 2016, 128, 4368-4368. | 1.4 | 0 |
| 132 | Calcium Mobilization in Unfavorable-Prognosis Chronic Lymphocytic Leukemia Patients Mediates Focal Adhesion Kinase (FAK) Cleavage, Thereby Its Activation. <i>Blood</i> , 2018, 132, 5537-5537. | 1.4 | 0 |
| 133 | Insights into the Molecular Mechanism Accounting for Neutropenia in T-Large Granular Lymphocytes Leukemia. <i>Blood</i> , 2018, 132, 1575-1575. | 1.4 | 0 |
| 134 | Waldenström Macroglobulinemia in Young Patients Treated in the Modern Era: A Multi-Institutional Italian Study. <i>Blood</i> , 2019, 134, 1539-1539. | 1.4 | 0 |
| 135 | Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HROoL) Analysis of the International Robust Study. <i>Blood</i> , 2019, 134, 3475-3475. | 1.4 | 0 |
| 136 | Overexpression and Targeted Activation of the Protein Phosphatases SHP-1 Abrogates Survival Pathways in Large Granular Lymphocyte Leukemia (LGLL). <i>Blood</i> , 2019, 134, 2798-2798. | 1.4 | 0 |
| 137 | Whole Exome Sequencing Analysis in Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK) Patients Fails to Detect Significant Viral Load. <i>Blood</i> , 2019, 134, 5214-5214. | 1.4 | 0 |
| 138 | Circular RNA Dysregulation Characterizes Symptomatic T-LGL Leukemia Patients with <i>STAT3</i> Mutation. <i>Blood</i> , 2021, 138, 1134-1134. | 1.4 | 0 |